With the recent 2021 update of the WHO Classification of Central Nervous System Tumours, homozygous deletions of CDKN2A/B are sufficient to designate meningiomas as CNS WHO grade 3 tumors regardless of histological grading [2]. This evidence concerns the gene CDKN2A and meningioma.